Selected article for: "infection rate and symptomatic infection"
Author: Harada, Kaoru; Ho, Hsi-en; Cunningham-Rundles, Charlotte
Title: COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City
  • Cord-id: dttlyn29
  • Document date: 2021_7_21
    • ID: dttlyn29
    Snippet: To better understand COVID-19 infection in patients receiving biologic and immunomodulatory therapies, we evaluated prevalence and outcomes for symptomatic cases of COVID-19 at a large therapeutic infusion center in New York City during the height of the pandemic. 2074 patients received treatment with biologic infusions at our center between March and May 2020, and 34 patients developed symptomatic COVID-19 infection, for an overall low rate of 1.64%. The majority of infections and deaths were i
    Document: To better understand COVID-19 infection in patients receiving biologic and immunomodulatory therapies, we evaluated prevalence and outcomes for symptomatic cases of COVID-19 at a large therapeutic infusion center in New York City during the height of the pandemic. 2074 patients received treatment with biologic infusions at our center between March and May 2020, and 34 patients developed symptomatic COVID-19 infection, for an overall low rate of 1.64%. The majority of infections and deaths were in a small subset of patients with a primary immunodeficiency. Patients with inflammatory or autoimmune conditions requiring biologic therapies tended to have mild cases. Higher inflammatory responses were observed in patients who died.

    Search related documents:
    Co phrase search for related documents
    • acid amplification and admission prior: 1, 2, 3
    • activator kinase signal transducer and acute response: 1
    • activator kinase signal transducer and lung disease: 1, 2
    • activator kinase signal transducer and lupus erythematosus: 1
    • acute response and admission prior: 1
    • acute response and admission require: 1, 2
    • acute response and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute response and lupus erythematosus: 1, 2, 3, 4
    • acute response cytokine and lung disease: 1
    • additional co and lung disease: 1
    • admission prior and lung disease: 1, 2, 3, 4, 5, 6
    • admission require and low incidence: 1
    • admission require and lung disease: 1, 2, 3, 4, 5, 6, 7